Lipid nanoparticle technology for therapeutic gene regulation in the liver.
Journal Information
Full Title: Adv Drug Deliv Rev
Abbreviation: Adv Drug Deliv Rev
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declaration of Competing Interest PRC is a co-founder of Acuitas Therapeutics and Precision Nanosystems; and Scientific Director and CEO of the NMIN."
"AcknowledgementsPRC acknowledges support from the Canadian Institutes for Health Research (FDN 148469) and the NanoMedicines Innovation Network (NMIN), a Canadian Networks of Centres of Excellence (NCE) in nanomedicine. DW is supported by the 10.13039/501100001711Swiss National Science Foundation (#183923). JAK is supported by the NMIN Postdoctoral Fellowship Award in Gene Therapy. JL is supported by a Frederick Banting and Charles Best Canada Graduate Scholarship – Masters (6556). The work of RvdM is supported by the Netherlands Organization for Scientific Research (NWO, ZonMW Vici grant no. 016.176.622)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025